Bruno Carlos
Sangro Gómez-Acebo

2024

1. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma

   Biomolecules, Vol. 14, Núm. 6

2. Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

   JHEP Reports, Vol. 6, Núm. 8

3. Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies

   CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324

4. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

   Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457

5. From the Editor's Desk

   Journal of hepatology, Vol. 80, Núm. 2, pp. 173-175

6. From the Editor's Desk.

   Journal of Hepatology

7. From the Editor's Desk.

   Journal of Hepatology

8. From the Editor's Desk...

   Journal of Hepatology

9. From the Editor's Desk...

   Journal of Hepatology

10. From the Editor's Desk...

    Journal of Hepatology

11. From the Editor's Desk…

    Journal of Hepatology

12. From the Editor's Desk…

    Journal of Hepatology

13. Himalaya Overall Survival Prominence and Other Routes to the Peak

    JAMA Oncology

14. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU

    Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113

15. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

16. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents for the Treatment of Liver Malignancy

    Journal of Vascular and Interventional Radiology, Vol. 35, Núm. 9, pp. 1253-1267.e1

17. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

18. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391

19. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

20. Patient-Reported Outcomes from the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma

    Journal of Clinical Oncology, Vol. 42, Núm. 23, pp. 2790-2799